Typological Study of Sleep Pathologies During Psoriatic Rheumatism and SAPHO Syndrome: Prospective Study Within the Paris Saint-Joseph Hospital Group"

NCT07086599 | Recruiting

• 2 other identifiers: 642-SleepSO22023-A01037-38
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic inflammatory rheumatisms (CIR) are a source of motor disability and various comorbidities, particularly cardiovascular and metabolic. They also significantly impact patients' quality of life, including sleep disturbances. Among CIRs, psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis, typically seronegative for rheumatoid factor. This heterogeneous disease affects peripheral and/or axial joints and can include extra-articular manifestations such as uveitis and chronic inflammatory bowel diseases. Its prevalence is estimated between 0.3% and 1% in the general population. SAPHO syndrome, similar to psoriatic arthritis, is characterized by specific bone involvement with a hypertrophic tendency, often affecting the axial skeleton and the anterior thoracic wall. Pain and inflammation are closely linked to sleep quality, creating a vicious cycle where pain disrupts sleep and poor sleep amplifies pain perception. Analgesic treatments, such as opioids, can also cause nocturnal respiratory pathologies, further disrupting sleep. Inflammatory processes are regulated by sleep, influencing plasma concentrations of CRP, IL6, and TNF production. Patients with psoriatic arthritis or SAPHO syndrome share common risk factors with Obstructive Sleep Apnea Syndrome (OSAS), such as obesity, hypertension, and metabolic syndrome. Sleep disorders are common in the general population and likely underdiagnosed in these patients. Several studies suggest a link between sleep disorders and these rheumatic conditions, affecting quality of life and exacerbating symptoms. Questionnaires like the Epworth and Pichot scales provide a more precise evaluation of these symptoms. However, objective sleep exploration through polysomnography has never been conducted in these patients. In summary, CIRs, particularly psoriatic arthritis and SAPHO syndrome, significantly impact patients' quality of life and sleep, necessitating appropriate evaluation and management of associated sleep disorders.

Conditions

Psoriasis Arthritis; SAPHO Syndrome; Sleep Apnea Syndromes

Outcome Measures

Primary Outcomes (1)

• Type of sleep disorders

  sleep disorders will be defined after polysomnography exam.

  at 6months

Secondary Outcomes (8)

• sleep structure

  at 6 months

• presence and severity of asthenia,

  at enrollement

• evaluation of anxiety

  at enrollement

• drowsiness evaluation

  at enrollement

• Evaluation of Sleep Apnea

  at enrollement, at 6months and at 12 months

Study Arms (3)

No sleep disorder

sleep apnea

other sleep disorder

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patient diagnosed with psoriasis arthritis or SAPHO syndrome and presenting sleep disorder

You may qualify if:

• Patient aged 18 years or older
• Patient diagnosed with psoriatic arthritis or SAPHO syndrome and followed at Paris Saint-Joseph Hospital
• Patient presenting sleep disorders warranting hospitalization for further -investigation of these disorders
• French-speaking patient
• Patient who does not oppose participation in the research protocol

You may not qualify if:

• Patient already followed for a sleep disorder
• Patient who underwent polysomnography in the last 2 years
• End-of-life patient
• Patient under guardianship or curatorship
• Patient deprived of liberty
• Patient under legal protection

Sponsors & Collaborators

• Fondation Hôpital Saint-Joseph: lead

Study Sites (1)

Hôpital Paris Saint Joseph

Paris, France

RECRUITING

MeSH Terms

Conditions

Acquired Hyperostosis Syndrome; Sleep Apnea Syndromes

Condition Hierarchy (Ancestors)

Osteochondrodysplasias; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases

Central Study Contacts

Juliette COURTIADE MAHLER

CONTACT

+33144127963; jcourtiade@ghpsj.Fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 18, 2025
• First Posted: July 25, 2025
• Study Start: November 13, 2023
• Primary Completion (Estimated): May 13, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: July 25, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)